You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Shreveport, Louisiana 71130

  • Squamous Cell Carcinoma

Purpose:

This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.


Criteria:

Inclusion Criteria: - Subjects with newly diagnosed, advanced stage, head and neck squamous cell carcinoma of the oral cavity, oral pharynx, hypopharynx or larynx. - Subjects willing to undergo tumor biopsies. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. - Age >/= 18 years. Exclusion Criteria: - Subjects receiving anticoagulation therapy. - Presence of unstable angina, recent myocardial infarction (within the previous 6 months), or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia. - Prior cancer therapy (chemotherapy, hormonal therapy, radiotherapy, immunotherapy) or investigational agent for their head and neck cancer.


NCT ID:

NCT00195299


Primary Contact:

Study Director
Medical Monitor
Wyeth


Backup Contact:

N/A


Location Contact:

Shreveport, Louisiana 71130
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.